Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials

PLoS ONE

Volumn 13, Issue 4, 2018, Pages

  Laranjeira, Fernanda O ^a   de Andrade, Keitty R C ^a   Figueiredo, Ana C M G ^a   Silva, Everton N ^a   Pereira, Mauricio G ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; METHODOLOGY; NOCTURNAL HYPOGLYCEMIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; CHEMISTRY; HYPOGLYCEMIA; REGRESSION ANALYSIS; STATISTICAL MODEL;

DIABETES MELLITUS, TYPE 1; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN, LONG-ACTING; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS;

EID: 85045469246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0194801     Document Type: Review

References (87)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. J Med. 1993 Sep 30; 329(14):977–86. https://doi.org/10.1056/NEJM199309303291401 PMID: 8366922
2. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001; 139(6):804–12. PMID: 11743505
3. National Institute for Clinical Excellence. Type 1 diabetes: the diagnosis and management of type 1 diabetes in adults. Clinical Guideline #15, 2004. Update In progress. Disponível em: www.nice.org.uk/CG015NICEguideline.
4. Nathan DM; DCCT/Edic Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014 Jan 1; 37 (1):9–16. https://doi.org/10.2337/dc13-2112 PMID: 24356592
5. Gomes MB, Coral M, Cobas RA, Dib SA, Canani LH, Nery M, et al. Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: a nationwide multicenter study in Brazil. Diabetes Res Clin Pract. 2012; 97:63–70. https://doi.org/10.1016/j.diabres.2012.02.008 PMID: 22397904
6. International Diabetes Federation. IDF Diabetes Atlas. 2015. Disponível em: www.idf.org/diabetesatlas.
7. Russell JD, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004; 26:724–36. PMID: 15220016
8. Home P, Bartley P, Russell JD, Hanaire BH, Heeg JE, Abrams P, et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004; 27:1081–7. PMID: 15111525
9. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008; 25:442–9. https://doi.org/10.1111/j.1464-5491.2007.02407.x PMID: 18387078
10. Tricco C, Ashoor M, Antony J, Beyene J, Veroniki A, Isaranuwatchai W, et al. And cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: Systematic review and network meta-analysis. BMJ. 2014 Oct 1; 349(g5459):1–13.
11. Sanches AC, Correr CJ, Venson R, Pontarolo R. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons. Diabetes Res Clin Pract. 2011; 94: 333–9. https://doi.org/10.1016/j.diabres.2011.09.001 PMID: 21992870
12. William T, Cefalu MD. American Diabetes Association standards of medical care in diabetes 2016. Diabetes Care January 2016; 39(supp 1): S1–S2.
13. Doničová V, Brož J, Sorin I. Health Care Provision for People with Diabetes and Postgraduate Training of Diabetes Specialists in Eastern European Countries. Journal of Diabetes Science and Technology. 2011 Sep, 5(5):1124–36. https://doi.org/10.1177/193229681100500513 PMID: 22027305
14. Pollock M, Fernandes M, Becker LA, Featherstone R, Hartling L. What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary. Pollock et al. Systematic Reviews. 2016; 5 (1):190. https://doi.org/10.1186/s13643-016-0367-5 PMID: 27842604
15. Becker LA, Oxman AD. Chapter 22: Overviews of reviews. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. 2011 March. Disponível em: www.cochrane-handbook.org.
16. Cheung A, Weir M, Mayhew A, Kozloff N, Brown K, Grimshaw J. Overview of systematic reviews of the effectiveness of reminders in improving healthcare professional behavior. Systematic reviews. 2012 Aug 16; 1(1):1.
17. Holden E, Currie J. Do the benefits of analog insulins justify their costs? Diabetes Manage. 2012; 2 (3):173–5.
18. Grunberger G. Insulin Analogs: Are They Worth It? Yes! Diabetes Care. 2014; 37:1767–70. https://doi.org/10.2337/dc14-0031 PMID: 24855159
19. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003; 26:1490–6. PMID: 12716810
20. Shea J, Grimshaw M, Wells A, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC medical research methodology. 2007 Feb 15; 7(1):1.
21. Jadad R, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17(1):1–12. PMID: 8721797
22. Higgins P, Thompson G, Deeks J, Altman G. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120
23. Sterne C, Kirkwood R. Essential Medical Statistics. 2Ed;2003.
24. Egger M, Davey G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–34. PMID: 9310563
25. Sterne A, Sutton J, Ioannidis P, Terrin N, Jones R, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011; 343 (d4002):1–8.
26. Wang F, Carabino M, Vergara M. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003 Jun; 25(6):1541–77. PMID: 12860485
27. Warren E. Weatherley E. Chilcott J. Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment 2004 8(45):3–41.
28. Mullins P, Sharplin P, Yki H, Riddle C, Haring U. Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics. 2007; 29(8):1607–19. https://doi.org/10.1016/j.clinthera.2007.08.020PMID: 17919543
29. Tran K, Banerjee S, Li H, Cimon K, Daneman D, Simpson SH, et al. Long-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. Technology Report number 92. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
30. Vardi M. Jacobson E. Nini A. Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews. 2008; 4(CD006297):3.
31. Singh R, Ahmad F, Lal A, Yu C, Bai Z, Bpharm B. Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 2009; 180(4): 385–97. https://doi.org/10.1503/cmaj.081041 PMID: 19221352
32. Szypowska A, Golicki D, Groele L, Pańkowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn. 2011 Jul-Aug; 121(7–8):237–46. PMID: 21878861
33. Frier M, Russell JD, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (iso-phane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab. 2013 Nov; 15 (11):978–86. https://doi.org/10.1111/dom.12106 PMID: 23551900
34. Souza CAL, de Assis AF, Guerra AA Jr, Rezende MNRC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014 Feb; 12(1):19–32. https://doi.org/10.1007/s40258-013-0073-6 PMID: 24385261
35. Szypowska A, Golicki D, Groele L, Pańkowska. Better metabolic control, less hypoglycemia and less weight gain with insulin detemir versus NPH insulin in intensive insulin therapy for patients with type 1 diabetes. A meta-analysis. Diabetologia. 2009; 52(S1):S387.
36. Sanches ACC, Correr CJ, Venson R, Gonçalves PR, Garcia MM, Piantavini MS, et al. Insulin analogues Versus Human Insulin in Type 1 diabetes: Direct and indirect meta-analyses of efficacy and safety. Brazilian Journal of Pharmaceutical Sciences. 2013; 49(3):501–9.
37. Godman B, De Souza A, Acurcio F, Guerra A Jr. Insulin glargine in a Brazilian state: An assessment of drug utilization, effectiveness and value to provide future direction. Basic and Clinical Pharmacology and Toxicology. 2014; 115(Suppl 1):72.
38. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000; 23:1666–71. PMID: 11092290
39. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000; 23:639–43. PMID: 10834423
40. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal- bolus therapy. Diabetes Care. 2001; 24(2):296–301. PMID: 11213882
41. Schober E, Schoenle E, Van Dyk J, Wernicke PK, The Pediatric Study Group on Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002; 15:369–76. PMID: 12008682
42. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003; 26:1490–6. PMID: 12716810
43. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003; 26:590–6. PMID: 12610006
44. Murphy NP, Keane SM, Ong KK, Ford AM, Edge JA, Acerini CL. Dunger DB: Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003; 26:799–804. PMID: 12610040
45. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004; 21:1213–20. https://doi.org/10.1111/j.1464-5491.2004.01323.x PMID: 15498088
46. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004; 47:622–9. https://doi.org/10.1007/ s00125-004-1365-z PMID: 15298338
47. Home P, Bartley P, Russell JD, Hanaire BH, Abrams P, Landin OM, et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004; 27:1081–7. PMID: 15111525
48. Home P, Bartley P, Landin OM, Russell JD, Hylleberg B, Draeger E. Insulin detemir offers improved glycemic control, less weight gain, and flexible timing of administration compared to NPH insulin. Diabetes 2003; 52(Suppl.1): A122.
49. Russell JD, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004; 26:724–36. PMID: 15220016
50. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther. 2004; 6:579–88. https://doi.org/10.1089/dia.2004.6.579 PMID: 15628811
51. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A; European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005 Nov-Dec; 21(6):545–53. https://doi.org/10.1002/dmrr.572 PMID: 16021649
52. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005; 35:536–42. https://doi.org/10.1111/j.1445-5994.2005.00902.x PMID: 16105155
53. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005; 22:850–7. https://doi.org/10.1111/j.1464-5491.2005.01545.x PMID: 15975098
54. Trial NN304-1476. Integrated Clinical Trial Report. 2015 Nov 07; (2): 1–8. Disponível em: http://www.novonordisktrials.com/website/pdf/registry/bin_20070524-020347-264.pdf
55. Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med. 2006; 23:285–92. https://doi.org/10.1111/j.1464-5491.2005.01781.xPMID: 16492212
56. Kolendorf K, Ross GP. Pavlic-Renar, Heller SR. Insulin detemir lowers the risk of hypoglycemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med. 2006; 23:729–35. https://doi.org/10.1111/j.1464-5491.2006.01862.x PMID: 16842476
57. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med. 2007; 24: 27–34. https://doi.org/10.1111/j.1464-5491.2007.02024.x PMID: 17227321
58. Chatterjee S, Jarvis KJ, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes—the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract. 2007; 77:215–22. https://doi.org/10.1016/j.diabres.2006.11.002 PMID: 17141354
59. Mianowska B, Szadkowska A, Czerniawska E, Pietrzak I, Bodalski J. Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes. Pediatr Endocrinol Diabetes Metab. 2007; 13:189–93. PMID: 18042313
60. Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 Diabetes Mellitus. J Pediatr. 2008; 153:547–53. https://doi.org/10.1016/j.jpeds.2008.04.063 PMID: 18589448
61. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008; 25:442–9. https://doi.org/10.1111/j.1464-5491.2007.02407.x PMID: 18387078
62. Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008; 121:466–72.
63. Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, et al. Lower fasting blood glucose, glucose variability and nocturnal hypoglycemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutrition, Metabolism & Cardiovascular Diseases. 2009; 19:571–9.
64. Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, et al. A randomized trial comparing the rate of hypoglycemia—assessed using continuous glucose monitoring—in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes. 2013 Dec; 14(8):593–601. https://doi.org/10.1111/pedi.12051 PMID: 23730996
65. Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial. Diabet Med. 2013 Feb; 30(2):216–25. https://doi.org/10.1111/dme.12041 PMID: 23094597
66. Pedersen BU, Kristensen PL, Beck NH, Norgaard K, Perrild H, Christiansen JS, et al. Effect of insulin analogues on risk of severe hypoglycemia in patients with type 1 diabetes prone to recurrent severe hypoglycemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014 Jul; 2(7):553–61. https://doi.org/10.1016/S2213-8587(14)70073-7PMID: 24794703
67. Bowker SL, Majumdar SR, Johnson JA. Systematic review of indicators and measurements used in controlled studies of quality improvement for type 2 diabetes. Can J Diabetes 2005; 29(3):230–8.
68. Gabriel EE, Gilbert PB. Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy. Biostatistics. 2014 Apr; 15(2):251–65. https://doi.org/10.1093/biostatistics/kxt055 PMID: 24337534
69. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. February 2008. Disponível em: http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf.
70. Rosenstock J, Park G, Zimmerman J, for the U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000; 23:1137–42. PMID: 10937511
71. Pieber TR, Eugene JI, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care. 2000; 23:157–62. PMID: 10868824
72. American Diabetes Association Workgroup on Hypoglycemia. Defining and Reporting Hypoglycemia in Diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005 May; 28(5): 1245–9. PMID: 15855602
73. Ly TT, Maahs DM, Rewers A, Dunger D, Oduwole A, Jones TW. International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2014 Sep; 15 Suppl 20:180–92.
74. Tsujino D, Nishimura R, Onda Y, Seo C, Ando K, Morimoto A, et al. The relationship between HbA1c values and the occurrence of hypoglycemia as assessed by continuous glucose monitoring in patients with type 1 diabetes. Diabetology & metabolic syndrome. 2016 Jul 29; 8(1):53.
75. ª ed, 2008.
76. Nathan DM, DCCT/Edic Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes care. 2014 Jan 1; 37 (1):9–16. https://doi.org/10.2337/dc13-2112 PMID: 24356592
77. Dawoud D, Fenu E, Wonderling D, O’Mahony R, Pursey N, Cobb J, et al. Basal insulin regimens: Systematic review, network meta-analysis, and cost-utility analysis for the National Institute for Health and Care Excellence (NICE) Clinical guideline on type 1 diabetes mellitus in adults. Value in Health 2015; 18(7): A339.
78. Dżygało K, Golicki D, Kowalska A, Szypowska A. The beneficial effect of insulin degludec on nocturnal hypoglycemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta diabetologica. 2015 Apr 1; 52(2):231–8. https://doi.org/10.1007/s00592-014-0604-0 PMID: 25430705
79. Esposito K, Chiodini P, Capuano A, Petrizzo M, Improta MR, Giugliano D. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes meta-analysis of randomized controlled trials. Diabetes Care. 2012 Dec 1; 35(12):2698–705. https://doi.org/10.2337/dc12-0698 PMID: 23173139
80. Bergenstal RM, Lincoff AM, Rodriguez A, Chen L, Qu Y, Prince MJ, et al. No difference in Major Adverse Cardiovascular Events (MACE plus) with Basal Insulin peglispro (BIL) vs comparator insulins in patients with type 1 or type 2 diabetes. Diabetologia 2015 Sep 1; 58:S65–S66.
81. Goldman J, White JR. New insulin glargine 300 U/mL for the treatment of type 1 and type 2 diabetes mellitus. Annals of Pharmacotherapy. 2015 Oct 1; 49(10):1153–61. https://doi.org/10.1177/ 1060028015597915 PMID: 26238470
82. Rys P, Wojciechowski P, Rogoz SA, Niesyczyński G, Lis J, Syta A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta diabetologica. 2015 Aug 1; 52(4):649–62. https://doi.org/10.1007/s00592-014-0698-4 PMID: 25585592
83. Linnebjerg H, Lam EC, Seger ME, Coutant D, Chua L, Chong CL, et al. Comparison of the pharmacoki-netics and pharmacodynamics of LY2963016 insulin glargine and EU-and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015 Dec 1; 38(12):2226–33. https://doi.org/10.2337/dc14-2623 PMID: 26307603
84. Heinemann L. Biosimilar Insulin and Costs What Can We Expect? J Diabetes Sci Technol. 2016 Mar; 10(2): 457–62.
85. Life Sciences & Transformational Health. Biosimilars Insulin Market: Global Industry Analysis and Forecast 2016–2024. Report code: PMRREP11674. Work in progress. March 2017. Disponível em: http://www.persistencemarketresearch.com/market-research/biosimilars-insulin-market.asp
86. Rotenstein LS, Ran N, Shivers JP, Yarchoan M, Close Kl. Opportunities and challenges for biosimilars: what’s on the horizon in the global insulin market? Clin Diabetes. 2012; 30:138–50.
87. Krentz AJ, Hompesch M. Biosimilar insulins: current and future perspectives. Diabetes Manag. 2015; 5 (6):405–9.